Kristin A Altwegg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4042278/publications.pdf

Version: 2024-02-01

1478505 1474206 9 120 9 6 citations h-index g-index papers 9 9 9 107 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2019, 18, 1341-1354.	4.1	41
2	LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer. Cell Death Discovery, 2021, 7, 216.	4.7	16
3	Interaction of transcription factor APâ€2 gamma with protoâ€oncogene PELP1 promotes tumorigenesis by enhancing RET signaling. Molecular Oncology, 2021, 15, 1146-1161.	4.6	15
4	SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance. Breast Cancer Research, 2022, 24, 26.	5.0	12
5	LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer. Communications Biology, 2021, 4, 1235.	4.4	11
6	PELP1 signaling contributes to medulloblastoma progression by regulating the NFâ€₽B pathway. Molecular Carcinogenesis, 2020, 59, 281-292.	2.7	9
7	Role of estrogen receptor coregulators in endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 2021, 2, 385-400.	0.8	6
8	Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab099.	0.7	5
9	Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC. Cancers, 2022, 14, 930.	3.7	5